After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...